Tempus AI, Inc. (TEM)
Market Cap | 12.82B |
Revenue (ttm) | 951.98M |
Net Income (ttm) | -199.73M |
Shares Out | 173.73M |
EPS (ttm) | -1.18 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 14,684,765 |
Open | 71.95 |
Previous Close | 71.59 |
Day's Range | 70.19 - 75.73 |
52-Week Range | 31.36 - 91.45 |
Beta | n/a |
Analysts | Buy |
Price Target | 65.36 (-11.41%) |
Earnings Date | Aug 8, 2025 |
About TEM
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]
Financial Performance
In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for TEM stock is "Buy." The 12-month stock price target is $65.36, which is a decrease of -11.41% from the latest price.
News

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade
Ark Invest CEO Cathie Wood is known for her stock picks over the last decade, handpicking many of the growth stocks that find their way into the company's ETFs.

Tempus AI Stock: Is It A Buy Following Guidance Raise?
Tempus AI delivered strong revenue growth and beat expectations on both revenue and profit, but remains unprofitable at this stage. Sequential improvements in both revenue and loss per share highlight...

TEM Investors Have Opportunity to Join Tempus AI, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tempus AI, Inc. ("Te...

Tempus AI: Buy or Sell TEM Stock At $65?
Tempus AI stock has increased by 10% over the past week, fueled by impressive quarterly results and a raised sales forecast for the entire year. The company is now predicting an 82% year-over-year inc...

Tempus AI, Inc. (TEM) Q2 2025 Earnings Call Transcript
Tempus AI, Inc. (NASDAQ:TEM) Q2 2025 Earnings Conference Call August 8, 2025 8:00 PM ET Company Participants Elizabeth Krutoholow - Vice President of Investor Relations & Competitive Intelligence Eri...
TEM Earnings Rally: A.I. Use in Health Care, Drug Discovery
George Congdon joins Morning Movers to look at an AI player in the healthcare space: Tempus AI (TEM). Shares of TEM have rallied higher after its 2Q earnings.

Tempus Reports Second Quarter 2025 Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

Tempus AI Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Tempus AI, Inc. TEM will release earnings results for the second quarter before the opening bell on Friday, Aug. 8.

Tempus AI: Next Leg Up
Tempus AI is appealing after a 10% pullback, seeing it as an opportunity following strong Q1 results and a short report-driven dip. The precision medicine company should top Q2 estimates, especially w...

Tempus AI: Data‑Driven Margin Lift, But Cash Burn Extends My Hold Stance
Tempus AI continues strong revenue growth, driven by its high-margin Data and Services segment and recent Ambry acquisition, but profitability remains elusive. Operational progress is evident, with ex...

Tempus AI: Sustaining Growth Momentum With Acquisitions & Partnerships
I am strongly bullish on Tempus AI due to its strategic partnerships, Ambry Genetics acquisition, and leadership in AI-driven precision oncology. Tempus' collaborations and acquisitions position it at...

Tempus to Report Second Quarter 2025 Financial Results on August 8
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 o...

Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearanc...

Apple Acquisition Buzz: Its $60 Billion War Chest Is Enough To Buy Datadog And Tempus
Apple Inc's AAPL massive $60+ billion cash pile is once again in the spotlight – and with rivals racing ahead in AI, investors are wondering: is it finally time for Apple to make a bold move?

Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication,...

Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathw...

Tempus AI: High-Growth And High-Risk
Tempus AI offers a compelling vision in precision oncology, boasting strong data assets, strategic partnerships, and rapid revenue growth. Valuation is rich, and execution risk is high—success depends...

Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $650 ...

Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to offer,...

Ambry Genetics' CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM) company and a leader in clinical genomic testing, announced today that a peer-revie...

Tempus AI Is Well Worth Its Price Tag
Tempus AI's innovation in genomics, data, and applications makes the company well positioned to become a contender in the AI healthcare space. Strong innovation is clearly translating into their finan...

Tempus to Participate in TD Cowen's 4th Annual Tools/Dx Revolution Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in TD Cowen's/Securities' 4th ...

Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025
MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Shamis & Gentile, P.A: To: All persons or entities who purchased or otherwise acquired Tempus AI, Inc. (“Tempus” or ...

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tempus AI, Inc. (TEM) and Encourages Shareholders to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tempus AI, Inc. ("Tempus" or "the Company") (NASDA...

Tempus Announces Collaboration with Northwestern University's Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer's Disease Research
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams...